Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Brain Neoplasms
  • Glioblastoma
  • Neoplasm Recurrence, Local
  • Protein Kinase Inhibitors
  • Protein Kinases
  • Sirolimus

abstract

  • Temsirolimus is well tolerated in recurrent GBM patients. Despite the effect of EIACs on temsirolimus metabolism, therapeutic levels were achieved. Radiographic improvement was observed in 36% of temsirolimus-treated patients, and was associated with significantly longer TTP. High levels of phosphorylated p70s6 kinase in baseline tumor samples appear to predict a patient population more likely to derive benefit from treatment. These findings should be validated in other studies of mTOR inhibitors.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.23.622

PubMed ID

  • 15998902

Additional Document Info

start page

  • 5294

end page

  • 304

volume

  • 23

number

  • 23